Schonfeld Strategic Advisors’s CorMedix CRMD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Buy	+30,153	New	+$238K	﹤0.01%	2133
2026 Q1	–	Sell	-43,431	Closed	-$505K	–	2297
2025 Q4	$505K	Buy	43,431 +22,283	+105%	+$246K	﹤0.01%	1394
2025 Q3	$246K	Buy	21,148 +5,266	+33%	+$63.7K	﹤0.01%	1892
2025 Q2	$196K	Buy	+15,882	New	+$175K	﹤0.01%	1793
2023 Q3	–	Sell	-14,255	Closed	-$56.5K	–	1851
2023 Q2	$56.5K	Buy	+14,255	New	+$70.5K	﹤0.01%	1800

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Schonfeld Strategic Advisors's CRMD Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in CorMedix (CRMD) in Q2 2026: 30,153 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #2133 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in CRMD as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in CRMD in Q2 2023 and has held it in 5 quarters since. The position peaked at $505K in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Schonfeld Strategic Advisors held 30,153 shares of CorMedix worth $237K as of Q2 2026.
CorMedix was a new Schonfeld Strategic Advisors position in Q2 2026.
CorMedix made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2133 holding.
Schonfeld Strategic Advisors first reported a position in CorMedix in Q2 2023 and has held it in 5 quarters since.
Schonfeld Strategic Advisors's CorMedix position peaked at $505K in Q4 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.